JCR Pharmaceuticals

Update in progress

4552.T (Tokyo)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

JCR Pharmaceuticals Co., Ltd., and its subsidiaries, develops, manufactures, imports, exports, and sells pharmaceutical products, regenerative medicines, and drug substances in Japan. Its products include GROWJECT for growth hormone deficiency, IZCARGO for MPS II, Agalsidase Beta BS I.V. Infusion for Fabry disease, and TEMCELL HS Inj for acute GVHD. It also develops Epoetin Alfa BS and Darbepoetin Alfa BS for renal anemia and trades medical devices. It collaborates with Angelini Pharma on novel biologics and with Modalis Therapeutics on CNS gene-delivery. Founded 1975; based in Ashiya, Japan.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.28; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive